Cargando…

Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement

BACKGROUND: The mechanically expandable Lotus Valve System is a fully repositionable and retrievable valve with an adaptive seal to minimize paravalvular leak (PVL). The aim of this study was to evaluate the short- and long-term safety and efficacy of the new device with focus on a new implantation...

Descripción completa

Detalles Bibliográficos
Autores principales: Berntorp, Karolina, Koul, Sasha, Nozohoor, Shahab, Harnek, Jan, Bjursten, Henrik, Götberg, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390309/
https://www.ncbi.nlm.nih.gov/pubmed/30808296
http://dx.doi.org/10.1186/s12872-019-1021-7
_version_ 1783398116166205440
author Berntorp, Karolina
Koul, Sasha
Nozohoor, Shahab
Harnek, Jan
Bjursten, Henrik
Götberg, Matthias
author_facet Berntorp, Karolina
Koul, Sasha
Nozohoor, Shahab
Harnek, Jan
Bjursten, Henrik
Götberg, Matthias
author_sort Berntorp, Karolina
collection PubMed
description BACKGROUND: The mechanically expandable Lotus Valve System is a fully repositionable and retrievable valve with an adaptive seal to minimize paravalvular leak (PVL). The aim of this study was to evaluate the short- and long-term safety and efficacy of the new device with focus on a new implantation technique to reduce the need for a permanent pacemaker (PPM) post procedure. METHODS: We performed a prospective single-center, non-randomized evaluation of the Lotus Valve System. The first 100 consecutive Lotus Valve implantations were included in the analysis. Outcome was assessed according to VARC2-criteria. Postoperative pacemaker rates were assessed using the national pacemaker registry and electronic medical records. Mortality at 30 days and 12 months were acquired from the national population registry. RESULTS: Mean age was 82.7 ± 5.6 years, mean Euroscore I was 25.3 ± 14.5%, mean STS-score was 6.5 ± 4.1% and mean aortic valve area was 0.6 ± 0.1 cm(2). There were no cases of valve embolization, ectopic valve deployment or additional valve implantation. Device success according to the VARC2-criteria was 97%. The 30-day mortality rate was 3%. Two deaths occurred due to stroke and one due to a ventricular rupture. Major stroke rate was 2% and major vascular complication rate was 2%. The 12-month mortality rate was 14%. At discharge 87% of patients had no/trace PVL, 12% had mild PVL and one patient had a moderate PVL. A total of 13% received a new PPM post valve implantation. Among patients who did not have a PPM before the procedure, the PPM rate was 15.3%. CONCLUSIONS: This single-center evaluation of the Lotus Valve System demonstrated a good clinical outcome with a low mortality, in a high-risk population. Introduction of a new implantation technique resulted in lower PPM rates than previously reported without negatively affecting PVL. TRIAL REGISTRATION: Current Controlled Trials ISRCTN14952278, retrospectively registered 06/11/2017.
format Online
Article
Text
id pubmed-6390309
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63903092019-03-19 Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement Berntorp, Karolina Koul, Sasha Nozohoor, Shahab Harnek, Jan Bjursten, Henrik Götberg, Matthias BMC Cardiovasc Disord Research Article BACKGROUND: The mechanically expandable Lotus Valve System is a fully repositionable and retrievable valve with an adaptive seal to minimize paravalvular leak (PVL). The aim of this study was to evaluate the short- and long-term safety and efficacy of the new device with focus on a new implantation technique to reduce the need for a permanent pacemaker (PPM) post procedure. METHODS: We performed a prospective single-center, non-randomized evaluation of the Lotus Valve System. The first 100 consecutive Lotus Valve implantations were included in the analysis. Outcome was assessed according to VARC2-criteria. Postoperative pacemaker rates were assessed using the national pacemaker registry and electronic medical records. Mortality at 30 days and 12 months were acquired from the national population registry. RESULTS: Mean age was 82.7 ± 5.6 years, mean Euroscore I was 25.3 ± 14.5%, mean STS-score was 6.5 ± 4.1% and mean aortic valve area was 0.6 ± 0.1 cm(2). There were no cases of valve embolization, ectopic valve deployment or additional valve implantation. Device success according to the VARC2-criteria was 97%. The 30-day mortality rate was 3%. Two deaths occurred due to stroke and one due to a ventricular rupture. Major stroke rate was 2% and major vascular complication rate was 2%. The 12-month mortality rate was 14%. At discharge 87% of patients had no/trace PVL, 12% had mild PVL and one patient had a moderate PVL. A total of 13% received a new PPM post valve implantation. Among patients who did not have a PPM before the procedure, the PPM rate was 15.3%. CONCLUSIONS: This single-center evaluation of the Lotus Valve System demonstrated a good clinical outcome with a low mortality, in a high-risk population. Introduction of a new implantation technique resulted in lower PPM rates than previously reported without negatively affecting PVL. TRIAL REGISTRATION: Current Controlled Trials ISRCTN14952278, retrospectively registered 06/11/2017. BioMed Central 2019-02-26 /pmc/articles/PMC6390309/ /pubmed/30808296 http://dx.doi.org/10.1186/s12872-019-1021-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Berntorp, Karolina
Koul, Sasha
Nozohoor, Shahab
Harnek, Jan
Bjursten, Henrik
Götberg, Matthias
Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
title Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
title_full Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
title_fullStr Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
title_full_unstemmed Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
title_short Single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
title_sort single-center evaluation of a next generation fully repositionable and retrievable transcatheter aortic valve replacement
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390309/
https://www.ncbi.nlm.nih.gov/pubmed/30808296
http://dx.doi.org/10.1186/s12872-019-1021-7
work_keys_str_mv AT berntorpkarolina singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement
AT koulsasha singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement
AT nozohoorshahab singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement
AT harnekjan singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement
AT bjurstenhenrik singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement
AT gotbergmatthias singlecenterevaluationofanextgenerationfullyrepositionableandretrievabletranscatheteraorticvalvereplacement